JUL 17, 2018 01:35 PM PDT

First Drug for Smallpox Treatment

WRITTEN BY: Nouran Amin

TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox, was just approved by the U.S. Food and Drug Administration to SIGA Technologies Inc. The development of TPOXX was in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

Even though eradicated in 1980, the World Health Organization (WHO) announced that smallpox as a contagious and sometimes fatal infectious disease that can be used as a bioweapon.

“To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon,” said FDA Commissioner Scott Gottlieb, M.D. "This is the first product to be awarded a Material Threat Medical Countermeasure priority review voucher. Today’s action reflects the FDA’s commitment to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products.”

Before its 1980 eradication, variola virus, the virus that leads to smallpox, it was mainly spread by direct contact between people. The symptoms typically began 10 to 14 days after infection and include fever, exhaustion, headache, and backache followed by a rash initially with small, pink bumps progressed to pus-filled sores before finally crusting over and scarring. Smallpox complications include encephalitis (inflammation of the brain), corneal ulcerations (an open sore on the clear, front surface of the eye) and blindness.

The efficacy of TPOXX against smallpox was concluded by studies on animals infected with viruses that are closely related to the virus that results in smallpox and was based on measuring survival at the end of the studies. The studies showed that the animals treated with TPOXX have survived compared to the animals treated with a placebo.

Using the FDA’s Animal Rule, which ensures efficacy are adequate from well-controlled animal research findings, TPOXX was approved.

TPOXX safety was evaluated using clinical trials on 359 healthy human volunteers without a smallpox infection and the most frequently reported side effects included a headache, nausea, and abdominal pain. Additionally, TPOXX received the Orphan Drug designation, which allows incentives to assist and inspire the development of drugs for rare diseases and a Material Threat Medical Countermeasure Priority Review Voucher, which provides additional incentives for specific medical products intended to treat or prevent harm from specific chemical, biological, radiological and nuclear threats.

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 05, 2018
Drug Discovery
JUN 05, 2018
Efficacy of 'Ribavirin Treatment' in Hemorrhagic Fever
Up to 40% of people die from a viral hemorrhagic disease and until now physicians cannot agree if the only treatment available, an antiviral drug by the na...
JUN 06, 2018
Drug Discovery
JUN 06, 2018
Computer Simulations Offer Alternative Methods for Diabetic Drugs
The Governor's Chair for Molecular Biophysics at the University of Tennessee (Knoxville), Jeremy Smith, and the director for the Center for Molecular B...
JUN 12, 2018
Drug Discovery
JUN 12, 2018
An Acetylcholine Blocker May Prevent Drug Addiction Relapse
It may sound like a paradox to produce a drug that is used to treat a drug addiction but scitnfcially speaking this is a logical possibility according to s...
AUG 20, 2018
Drug Discovery
AUG 20, 2018
Drug Seeks To Prevent a Painful Side-Effect
Many patients with head, neck, nasal, and oral cancers are treated with radiations. Unfortunately, such treatment leaves patients with a painful side-effec...
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Alternative Therapy for Peripheral Artery Disease
To fight peripheral artery diseases (PAD), an “ailment affecting 8 million Americans”, researchers at LSU School of Veterinary Medicine have di...
SEP 02, 2018
Genetics & Genomics
SEP 02, 2018
Insights From the Opium Poppy Genome
By sequencing the opium poppy's DNA, scientists have revealed important details about how it makes its medicine....
Loading Comments...